Anavex Life Sciences (NASDAQ:AVXL - Get Free Report)'s stock had its "buy" rating restated by stock analysts at D. Boral Capital in a report released on Wednesday,Benzinga reports. They currently have a $46.00 price target on the biotechnology company's stock. D. Boral Capital's target price suggests a potential upside of 439.91% from the stock's current price.
Separately, HC Wainwright reissued a "buy" rating and issued a $42.00 target price on shares of Anavex Life Sciences in a report on Tuesday, January 28th.
Read Our Latest Report on AVXL
Anavex Life Sciences Stock Performance
Shares of AVXL traded up $0.05 during midday trading on Wednesday, hitting $8.52. The company had a trading volume of 838,214 shares, compared to its average volume of 1,356,018. The company's 50-day simple moving average is $9.94 and its 200-day simple moving average is $7.71. The firm has a market capitalization of $722.67 million, a P/E ratio of -16.38 and a beta of 0.69. Anavex Life Sciences has a 1 year low of $3.25 and a 1 year high of $14.44.
Anavex Life Sciences (NASDAQ:AVXL - Get Free Report) last posted its earnings results on Wednesday, February 12th. The biotechnology company reported ($0.14) earnings per share for the quarter, topping the consensus estimate of ($0.17) by $0.03. Equities analysts predict that Anavex Life Sciences will post -0.73 earnings per share for the current fiscal year.
Hedge Funds Weigh In On Anavex Life Sciences
Institutional investors have recently added to or reduced their stakes in the business. Tower Research Capital LLC TRC increased its stake in Anavex Life Sciences by 102.0% during the fourth quarter. Tower Research Capital LLC TRC now owns 3,383 shares of the biotechnology company's stock worth $36,000 after acquiring an additional 1,708 shares during the last quarter. Berkshire Money Management Inc. acquired a new stake in Anavex Life Sciences during the fourth quarter worth about $107,000. Prudential Financial Inc. acquired a new stake in Anavex Life Sciences during the fourth quarter worth about $109,000. Fiduciary Alliance LLC acquired a new stake in Anavex Life Sciences during the fourth quarter worth about $119,000. Finally, D.A. Davidson & CO. acquired a new stake in shares of Anavex Life Sciences in the fourth quarter valued at about $122,000. 31.55% of the stock is currently owned by institutional investors and hedge funds.
About Anavex Life Sciences
(
Get Free Report)
Anavex Life Sciences Corp., a clinical stage biopharmaceutical company, engages in the development of therapeutics for the treatment of central nervous system diseases. Its lead product candidate is ANAVEX 2-73 for the treatment of Alzheimer's disease and Parkinson's disease, as well as other central nervous system diseases, including rare diseases, such as Rett syndrome, a rare severe neurological monogenic disorder; and infantile spasms, Fragile X syndrome, and Angelman syndrome.
See Also
Before you consider Anavex Life Sciences, you'll want to hear this.
MarketBeat keeps track of Wall Street's top-rated and best performing research analysts and the stocks they recommend to their clients on a daily basis. MarketBeat has identified the five stocks that top analysts are quietly whispering to their clients to buy now before the broader market catches on... and Anavex Life Sciences wasn't on the list.
While Anavex Life Sciences currently has a Buy rating among analysts, top-rated analysts believe these five stocks are better buys.
View The Five Stocks Here
Wondering when you'll finally be able to invest in SpaceX, Starlink, or X.AI? Enter your email address to learn when Elon Musk will let these companies finally IPO.
Get This Free Report
Like this article? Share it with a colleague.
Link copied to clipboard.
